Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Rhea-AI Summary
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing therapies for cancer and rare diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's management will present on Monday, September 9, 2024, at 1:30 pm ET in New York.
Investors and interested parties can access a live webcast of the presentation through the Events and Presentations section of Protara's website at https://ir.protaratx.com. The webcast will be available for a time after the presentation concludes, providing an opportunity for those unable to attend the live event to catch up on the company's latest developments and strategic outlook.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TARA declined 4.00%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on Monday, September 9, 2024 at 1:30 pm ET.
A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
When is Protara Therapeutics (TARA) presenting at the H.C. Wainwright Global Investment Conference?
How can I watch Protara Therapeutics' (TARA) presentation at the investment conference?
What does Protara Therapeutics (TARA) specialize in?
Will Protara Therapeutics' (TARA) conference presentation be available after the live event?
